← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Proteasome inhibitors
bortezomib
L01XG01
Forms & Strengths
- Injection: 3.5 mg lyophilized powder in single-dose vial for reconstitution
Adult Dosing
- Multiple Myeloma: 1.3 mg/m2 administered as a 3-5 second bolus intravenous injection or subcutaneous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle
- Mantle Cell Lymphoma: 1.3 mg/m2 IV or SC on Days 1, 4, 8, and 11 of a 21-day cycle (or 35-day cycle depending on regimen)
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of multiple myeloma
- Treatment of patients with mantle cell lymphoma
Mechanism of Action
- Reversible inhibitor of the 26S proteasome, disrupting multiple intracellular signaling cascades, preventing degradation of pro-apoptotic factors, and causing cell cycle arrest and apoptosis in cancer cells
Contraindications
- Hypersensitivity to bortezomib, boron, or mannitol
- Intrathecal administration (fatal)
Adverse Reactions
- Peripheral neuropathy (sensory and motor)
- Thrombocytopenia and neutropenia
- Peripheral edema
- Nausea, diarrhea, and constipation
- Neuralgia and fatigue
- Herpes zoster reactivation (antiviral prophylaxis recommended)
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase bortezomib exposure
- Strong CYP3A4 inducers (e.g., rifampin) may decrease bortezomib efficacy
- Coadministration with oral hypoglycemics may require blood glucose monitoring due to potential hypoglycemia or hyperglycemia
Curated Content: Needs Vetting Before Put to Clinical Use